Clinical Trial Update: A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pembrolizumab formulated with berahyaluronidase alfa (MK-5180) in Japanese participants with recurrent or metastatic cutaneous…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• Berahyaluronidase Alfa (berahyaluronidase alfa)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING